Growth Metrics

Tandem Diabetes Care (TNDM) Convertible Debt (2020 - 2026)

Tandem Diabetes Care filings provide 6 years of Convertible Debt readings, the most recent being $310.0 million for Q4 2025.

  • On a quarterly basis, Convertible Debt rose 0.57% to $310.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $310.0 million, a 0.57% increase, with the full-year FY2025 number at $310.0 million, up 0.57% from a year prior.
  • Convertible Debt hit $310.0 million in Q4 2025 for Tandem Diabetes Care, roughly flat from $309.6 million in the prior quarter.
  • In the past five years, Convertible Debt ranged from a high of $347.5 million in Q1 2024 to a low of $280.2 million in Q1 2021.
  • Median Convertible Debt over the past 5 years was $284.4 million (2023), compared with a mean of $295.0 million.
  • Biggest five-year swings in Convertible Debt: skyrocketed 43.64% in 2021 and later fell 11.16% in 2025.
  • Tandem Diabetes Care's Convertible Debt stood at $281.5 million in 2021, then increased by 0.63% to $283.2 million in 2022, then grew by 0.64% to $285.0 million in 2023, then increased by 8.15% to $308.3 million in 2024, then increased by 0.57% to $310.0 million in 2025.
  • The last three reported values for Convertible Debt were $310.0 million (Q4 2025), $309.6 million (Q3 2025), and $309.1 million (Q2 2025) per Business Quant data.